

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pa	atent Application of)			
Yong WEI et al.) Group Art Unit: 1615			
Application No.: 09/429,694		Examiner: G. S. Kishore			
Filed:	October 27, 1999	Confirmation No.: 62RECEIVED			
For:	LIPOSOMAL CERAMIDE-RELATED COMPOUNDS AND THE THERAPEUTIC USE THEREOF	APR 3 0 2003 TECH CENTER 1600/2900			
	AMENDMENT/REPLY TR	ANSMITTAL LETTER			
	nt Commissioner for Patents agton, D.C. 20231				
Sir:					
Er	aclosed is a reply for the above-identified pat	ent application.			
[A Petition for Extension of Time is also	enclosed.			
[[] A Terminal Disclaimer and the [] \$55.00 (2814) [] \$110.00 (1814) fee due under 37 C.F.R. § 1.20(d) are also enclosed.				
[Also enclosed is/are	·			
[Small entity status is hereby claimed.				
[Applicant(s) request continued examinati [] \$375.00 (2801) [] \$750.00 (1801) fe	on under 37 C.F.R. § 1.114 and enclose the e due under 37 C.F.R. § 1.17(e).			
	[] Applicant(s) previously submitted _ requested.	_, on, for which continued examination is			
[Applicant(s) request suspension of action exceed three months from the filing of th § 1.103(c). The required fee under 37 C				
[A Request for Entry and Consideration of (1809/2809) is also enclosed.	of Submission under 37 C.F.R. § 1.129(a)			

[X] No additional claim fee is required.

[] An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims	36	MINUS 57 =	0	× \$18.00 (1202) =	\$0.00
Independent Claims	2	MINUS 3 =	0	× \$84.00 (1201) =	0.00
If Amendment adds mu	ıltiple depend	ent claims, add \$280	0.00 (1203)		
Total Amendment Fee					0.00
If small entity status is	claimed, sub	tract 50% of Total A	mendment Fe	e	
TOTAL ADDITIONA	L FEE DUE	FOR THIS AMEN	NDMENT		\$0.00

[]	A claim fee in the	amount of \$	is	enclosed.
[]	Charge \$	to Deposit Account N	lo.	02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted


Burns, Doane, Sweeker & Mathis, L.L.P.

By:

Teresa Stanek Rea Registration No. 30,427

P.O. Box 1404 Alexandria, VA 22313-1404 (703) 836-6620

Date: April 29, 2003





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	atent Application of)		130	<u>, </u>
YONG	G WEI et al.)	Group Art Unit: 1615	5-3-	-6
Applic	cation No.: 09/429,694)	Examiner: G. S. Kishore		
Filed:	October 27, 1999)	Confirmation Number: 6218		
For:	LIPOSOMAL CERAMIDE-RELATED COMPOUNDS AND THE THERAPEUTIC USE THEREOF)	RECEIV	/ED	
	AMENDMENT		APR 3 0 2 ENT TECH CENTER 1	003 600/2900	

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In complete response to the Official Action issued January 31, 2002, Applicants respectfully request reconsideration and examination of this application in view of the following amendments and remarks.

IN THE CLAIMS:

Please cancel Claims 58-78, without prejudice or disclaimer.

Please add new Claims 79-99 as follows:

-- 79. (New) The method of claim 15, wherein the cancer is a brain, breast, lung, ovarian, colon, stomach or prostate cancer.

80. (New) The method of claim 15, wherein the cancer is a sarcoma, carcinoma, neuroblastoma, glioma or drug resistant cancer.